Global Lyme Disease Diagnostics Market

Lyme Disease Diagnostics Comprehensive Study by Diagnostic Technology (Serological Test (ELISA, Western Blot), Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nucleic acid Test), End User (Hospitals, Public/Private Laboratories, Others) Players and Region - Global Market Outlook to 2030

Lyme Disease Diagnostics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Lyme Disease Diagnostics Market Overview:
Lyme disease is a tick-borne infectious disease caused by Borrelia burgdorferi. Common symptoms of the Lyme disease are flu-like symptoms, rashes, bulls-eye pattern, weakness in the limbs, and joint pain. Rise in a number of patients with Lyme disease driving the demand for Lyme disease diagnostic market. For instance, according to the Centers for Disease Control and Prevention (CDC) every year, approximately 30,000 cases of Lyme disease are reported in the United States. Further, increasing investment in healthcare infrastructure in developing countries expected to drive the demand for Lyme disease diagnostic market over the forecasted period.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Emphasizing on the Technological Advancement in the Lyme disease Diagnostic Tests

Market Growth Drivers:
Increasing Prevalence of Lyme Disease and Growing Healthcare Infrastructure Globally

Challenges:
Inability to Identify the Initial Symptoms of Lyme Disease

Restraints:
High Initial Investment for Laboratory Setup of Lyme Disease Diagnosis and Lack of Awareness Regarding Lyme Disease In Emerging Economies

Opportunities:
Increasing Demand from Developing Economies and Rising Awareness about Early Diagnosis and Treatment

Competitive Landscape:
The market of Lyme Disease Diagnostics is expected to grow with rising incidence of lyme disease. Increasing prevalence cases and healthcare infrastructure driving the demand for the market. Several companies are operating in the market to provide Lyme Disease Diagnostics with various features & unique offering. The market is highly fragmented with the presence of several market players. They are gaining attention owing to their innovative and novel portfolio.
Some of the key players profiled in the report are Abbott Laboratories (United States), T2 Biosystems (United States), Canon Life Sciences (United States), Bio-Rad Laboratories (United States), Alere Inc. (United States), Roche Diagnostics International Ltd. (Switzerland), Graphene Frontiers (United States), Covance Inc. (United States), GlaxoSmithKline Pharmaceuticals Ltd. (India), Boulder Diagnostics (United States) and Thermo Fisher Scientific (United States). Additionally, following companies can also be profiled that are part of our coverage like Baxter International Inc. (United States), Fresenius Medical Care AG & Co. (Germany) and Oxford Immunotec (United Kingdom). Analyst at AMA Research see United States Players to retain maximum share of Global Lyme Disease Diagnostics market by 2030. Considering Market by Diagnostic Technology, the sub-segment i.e. Serological Test [ELISA, Western Blot] will boost the Lyme Disease Diagnostics market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Lyme Disease Diagnostics market.

Latest Market Insights:
In September 2021, Roche acquires TIB Molbiol . This acquisition expands Roche's portfolio of molecular diagnostics solutions, including polymerase chain reaction (PCR) tests, which are currently used for Lyme disease diagnosis.

In November 2019 , IGeneX, a leading tick-borne disease testing lab based in California, has launch the availability of the new Broad Coverage Ab (BCA) Assays for Lyme disease and Tick-Borne Relapsing Fever (TBRF).

"The Centers for Disease Control and Prevention (CDC) has developed a national Lyme disease risk map in which CDC identified areas of the United States as minimal or no risk, low risk, moderate risk, or high risk for predicted Lyme disease. "

What Can be Explored with the Lyme Disease Diagnostics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Lyme Disease Diagnostics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Lyme Disease Diagnostics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Lyme Disease Diagnostics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Lyme Disease Diagnostics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Lyme Disease Drug Manufacturers, Healthcare Association, Potential Investors, Government Organization, Market Research Firms, Research Associations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Diagnostic Technology
  • Serological Test [ELISA, Western Blot]
  • Urine Antigen Tests
  • Lymphocytic Transformation Test
  • Immunofluorescent Staining
  • Nucleic acid Test

By End User
  • Hospitals
  • Public/Private Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Lyme Disease
      • 3.2.2. Growing Healthcare Infrastructure Globally
    • 3.3. Market Challenges
      • 3.3.1. Inability to Identify the Initial Symptoms of Lyme Disease
    • 3.4. Market Trends
      • 3.4.1. Emphasizing on the Technological Advancement in the Lyme disease Diagnostic Tests
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lyme Disease Diagnostics, by Diagnostic Technology, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lyme Disease Diagnostics (Value)
      • 5.2.1. Global Lyme Disease Diagnostics by: Diagnostic Technology (Value)
        • 5.2.1.1. Serological Test [ELISA, Western Blot]
        • 5.2.1.2. Urine Antigen Tests
        • 5.2.1.3. Lymphocytic Transformation Test
        • 5.2.1.4. Immunofluorescent Staining
        • 5.2.1.5. Nucleic acid Test
      • 5.2.2. Global Lyme Disease Diagnostics by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Public/Private Laboratories
        • 5.2.2.3. Others
      • 5.2.3. Global Lyme Disease Diagnostics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Lyme Disease Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. T2 Biosystems (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Canon Life Sciences (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Alere Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Diagnostics International Ltd. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Graphene Frontiers (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Covance Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline Pharmaceuticals Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boulder Diagnostics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Thermo Fisher Scientific (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Lyme Disease Diagnostics Sale, by Diagnostic Technology, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lyme Disease Diagnostics (Value)
      • 7.2.1. Global Lyme Disease Diagnostics by: Diagnostic Technology (Value)
        • 7.2.1.1. Serological Test [ELISA, Western Blot]
        • 7.2.1.2. Urine Antigen Tests
        • 7.2.1.3. Lymphocytic Transformation Test
        • 7.2.1.4. Immunofluorescent Staining
        • 7.2.1.5. Nucleic acid Test
      • 7.2.2. Global Lyme Disease Diagnostics by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Public/Private Laboratories
        • 7.2.2.3. Others
      • 7.2.3. Global Lyme Disease Diagnostics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lyme Disease Diagnostics: by Diagnostic Technology(USD Million)
  • Table 2. Lyme Disease Diagnostics Serological Test [ELISA, Western Blot] , by Region USD Million (2018-2023)
  • Table 3. Lyme Disease Diagnostics Urine Antigen Tests , by Region USD Million (2018-2023)
  • Table 4. Lyme Disease Diagnostics Lymphocytic Transformation Test , by Region USD Million (2018-2023)
  • Table 5. Lyme Disease Diagnostics Immunofluorescent Staining , by Region USD Million (2018-2023)
  • Table 6. Lyme Disease Diagnostics Nucleic acid Test , by Region USD Million (2018-2023)
  • Table 7. Lyme Disease Diagnostics: by End User(USD Million)
  • Table 8. Lyme Disease Diagnostics Hospitals , by Region USD Million (2018-2023)
  • Table 9. Lyme Disease Diagnostics Public/Private Laboratories , by Region USD Million (2018-2023)
  • Table 10. Lyme Disease Diagnostics Others , by Region USD Million (2018-2023)
  • Table 11. South America Lyme Disease Diagnostics, by Country USD Million (2018-2023)
  • Table 12. South America Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 13. South America Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 14. Brazil Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 15. Brazil Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 16. Argentina Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 17. Argentina Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 18. Rest of South America Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 19. Rest of South America Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 20. Asia Pacific Lyme Disease Diagnostics, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 22. Asia Pacific Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 23. China Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 24. China Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 25. Japan Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 26. Japan Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 27. India Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 28. India Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 29. South Korea Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 30. South Korea Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 31. Taiwan Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 32. Taiwan Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 33. Australia Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 34. Australia Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 37. Europe Lyme Disease Diagnostics, by Country USD Million (2018-2023)
  • Table 38. Europe Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 39. Europe Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 40. Germany Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 41. Germany Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 42. France Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 43. France Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 44. Italy Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 45. Italy Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 46. United Kingdom Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 47. United Kingdom Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 48. Netherlands Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 49. Netherlands Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 50. Rest of Europe Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 51. Rest of Europe Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 52. MEA Lyme Disease Diagnostics, by Country USD Million (2018-2023)
  • Table 53. MEA Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 54. MEA Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 55. Middle East Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 56. Middle East Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 57. Africa Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 58. Africa Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 59. North America Lyme Disease Diagnostics, by Country USD Million (2018-2023)
  • Table 60. North America Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 61. North America Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 62. United States Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 63. United States Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 64. Canada Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 65. Canada Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 66. Mexico Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2018-2023)
  • Table 67. Mexico Lyme Disease Diagnostics, by End User USD Million (2018-2023)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Lyme Disease Diagnostics: by Diagnostic Technology(USD Million)
  • Table 80. Lyme Disease Diagnostics Serological Test [ELISA, Western Blot] , by Region USD Million (2025-2030)
  • Table 81. Lyme Disease Diagnostics Urine Antigen Tests , by Region USD Million (2025-2030)
  • Table 82. Lyme Disease Diagnostics Lymphocytic Transformation Test , by Region USD Million (2025-2030)
  • Table 83. Lyme Disease Diagnostics Immunofluorescent Staining , by Region USD Million (2025-2030)
  • Table 84. Lyme Disease Diagnostics Nucleic acid Test , by Region USD Million (2025-2030)
  • Table 85. Lyme Disease Diagnostics: by End User(USD Million)
  • Table 86. Lyme Disease Diagnostics Hospitals , by Region USD Million (2025-2030)
  • Table 87. Lyme Disease Diagnostics Public/Private Laboratories , by Region USD Million (2025-2030)
  • Table 88. Lyme Disease Diagnostics Others , by Region USD Million (2025-2030)
  • Table 89. South America Lyme Disease Diagnostics, by Country USD Million (2025-2030)
  • Table 90. South America Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 91. South America Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 92. Brazil Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 93. Brazil Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 94. Argentina Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 95. Argentina Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 96. Rest of South America Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 97. Rest of South America Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 98. Asia Pacific Lyme Disease Diagnostics, by Country USD Million (2025-2030)
  • Table 99. Asia Pacific Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 100. Asia Pacific Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 101. China Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 102. China Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 103. Japan Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 104. Japan Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 105. India Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 106. India Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 107. South Korea Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 108. South Korea Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 109. Taiwan Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 110. Taiwan Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 111. Australia Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 112. Australia Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 113. Rest of Asia-Pacific Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 114. Rest of Asia-Pacific Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 115. Europe Lyme Disease Diagnostics, by Country USD Million (2025-2030)
  • Table 116. Europe Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 117. Europe Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 118. Germany Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 119. Germany Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 120. France Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 121. France Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 122. Italy Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 123. Italy Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 124. United Kingdom Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 125. United Kingdom Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 126. Netherlands Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 127. Netherlands Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 128. Rest of Europe Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 129. Rest of Europe Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 130. MEA Lyme Disease Diagnostics, by Country USD Million (2025-2030)
  • Table 131. MEA Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 132. MEA Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 133. Middle East Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 134. Middle East Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 135. Africa Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 136. Africa Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 137. North America Lyme Disease Diagnostics, by Country USD Million (2025-2030)
  • Table 138. North America Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 139. North America Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 140. United States Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 141. United States Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 142. Canada Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 143. Canada Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 144. Mexico Lyme Disease Diagnostics, by Diagnostic Technology USD Million (2025-2030)
  • Table 145. Mexico Lyme Disease Diagnostics, by End User USD Million (2025-2030)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lyme Disease Diagnostics: by Diagnostic Technology USD Million (2018-2023)
  • Figure 5. Global Lyme Disease Diagnostics: by End User USD Million (2018-2023)
  • Figure 6. South America Lyme Disease Diagnostics Share (%), by Country
  • Figure 7. Asia Pacific Lyme Disease Diagnostics Share (%), by Country
  • Figure 8. Europe Lyme Disease Diagnostics Share (%), by Country
  • Figure 9. MEA Lyme Disease Diagnostics Share (%), by Country
  • Figure 10. North America Lyme Disease Diagnostics Share (%), by Country
  • Figure 11. Global Lyme Disease Diagnostics share by Players 2023 (%)
  • Figure 12. Global Lyme Disease Diagnostics share by Players (Top 3) 2023(%)
  • Figure 13. Global Lyme Disease Diagnostics share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 16. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 17. T2 Biosystems (United States) Revenue, Net Income and Gross profit
  • Figure 18. T2 Biosystems (United States) Revenue: by Geography 2023
  • Figure 19. Canon Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 20. Canon Life Sciences (United States) Revenue: by Geography 2023
  • Figure 21. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 23. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Alere Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Roche Diagnostics International Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Roche Diagnostics International Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 27. Graphene Frontiers (United States) Revenue, Net Income and Gross profit
  • Figure 28. Graphene Frontiers (United States) Revenue: by Geography 2023
  • Figure 29. Covance Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Covance Inc. (United States) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline Pharmaceuticals Ltd. (India) Revenue: by Geography 2023
  • Figure 33. Boulder Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Boulder Diagnostics (United States) Revenue: by Geography 2023
  • Figure 35. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 36. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 37. Global Lyme Disease Diagnostics: by Diagnostic Technology USD Million (2025-2030)
  • Figure 38. Global Lyme Disease Diagnostics: by End User USD Million (2025-2030)
  • Figure 39. South America Lyme Disease Diagnostics Share (%), by Country
  • Figure 40. Asia Pacific Lyme Disease Diagnostics Share (%), by Country
  • Figure 41. Europe Lyme Disease Diagnostics Share (%), by Country
  • Figure 42. MEA Lyme Disease Diagnostics Share (%), by Country
  • Figure 43. North America Lyme Disease Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • T2 Biosystems (United States)
  • Canon Life Sciences (United States)
  • Bio-Rad Laboratories (United States)
  • Alere Inc. (United States)
  • Roche Diagnostics International Ltd. (Switzerland)
  • Graphene Frontiers (United States)
  • Covance Inc. (United States)
  • GlaxoSmithKline Pharmaceuticals Ltd. (India)
  • Boulder Diagnostics (United States)
  • Thermo Fisher Scientific (United States)
Additional players considered in the study are as follows:
Baxter International Inc. (United States) , Fresenius Medical Care AG & Co. (Germany) , Oxford Immunotec (United Kingdom)
Select User Access Type

Key Highlights of Report


Jan 2024 232 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lyme Disease Diagnostics Market Quantitative research analysis
Global Lyme Disease Diagnostics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Lyme Disease Diagnostics market are Abbott Laboratories (United States), T2 Biosystems (United States), Canon Life Sciences (United States), Bio-Rad Laboratories (United States), Alere Inc. (United States), Roche Diagnostics International Ltd. (Switzerland), Graphene Frontiers (United States), Covance Inc. (United States), GlaxoSmithKline Pharmaceuticals Ltd. (India), Boulder Diagnostics (United States) and Thermo Fisher Scientific (United States), to name a few.
"Emphasizing on the Technological Advancement in the Lyme disease Diagnostic Tests" is seen as one of major influencing trends for Lyme Disease Diagnostics Market during projected period 2023-2030.

Know More About Global Lyme Disease Diagnostics Market Report?

Have a Query? Click Here

Other Related Reports

Psoriatic Arthritis Treatment Comprehensive Study by Treatment (Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others), Surgical Procedur...
$ 3750
Gene expression analysis Comprehensive Study by Type (Consumables (Reagents, DNA Chips), Instruments (PCR, NGS, Microarray)), Application (Diagnostics, Pharmacogenomics, Toxicology, Compare Expressio...
$ 3750
Edible Vaccines Comprehensive Study by Type (Inactivated Vaccines, Others), Application (Medical Care, Livestock, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Valley Fever Treatment Comprehensive Study by Application (People, Cattle, Sheep and Goats, Camel, Others), Treatment for Pets (Fluconazole (Diflucan), Itraconazole (Sporanox), Ketoconazole (Nizoral)...
$ 3450
Primary Immunodeficiency Diseases Treatment Comprehensive Study by Type (Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, Others), Applicat...
$ 3800
Craniomaxillofacial Implants Comprehensive Study by Type (Titanium and Alloys, Polymers/Biomaterials, Calcium Phosphate Ceramics), Application (External Fixators, Internal Fixators), Material (Metal...
$ 3800